Details for New Drug Application (NDA): 211422

NDA 211422 describes FULVESTRANT, which is a drug marketed by Accord Hlthcare, Alembic, Amneal, Apotex, Avyxa Holdings, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Glenmark Pharms Inc, Hbt Labs Inc, Jiangsu Hansoh Pharm, Sagent Pharms Inc, Sandoz, Xiromed, and Zydus Pharms, and is included in seventeen NDAs. It is available from nineteen suppliers. There are three patents protecting this drug. Additional details are available on the FULVESTRANT profile page.

The generic ingredient in FULVESTRANT is fulvestrant. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fulvestrant profile page.

Summary for 211422

Tradename:	FULVESTRANT
Applicant:	Chia Tai Tianqing
Ingredient:	fulvestrant
Patents:	0

Pharmacology for NDA: 211422

Mechanism of Action

Estrogen Receptor Antagonists Selective Estrogen Receptor Modulators

Suppliers and Packaging for NDA: 211422

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
FULVESTRANT	fulvestrant	SOLUTION;INTRAMUSCULAR	211422	ANDA	Sagent Pharmaceuticals	25021-471	25021-471-74	2 SYRINGE in 1 CARTON (25021-471-74) / 5 mL in 1 SYRINGE
FULVESTRANT	fulvestrant	SOLUTION;INTRAMUSCULAR	211422	ANDA	Athenex Pharmaceutical Division, LLC.	70860-211	70860-211-74	2 SYRINGE, GLASS in 1 CARTON (70860-211-74) / 5 mL in 1 SYRINGE, GLASS (70860-211-41)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAMUSCULAR			Strength	250MG/5ML (50MG/ML)
Approval Date:	Feb 7, 2020	TE:	AO	RLD:	No

Complete Access Available with Subscription